Latest news and press releases about Clene Inc. (CLNN): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
Clene Inc. is a biopharmaceutical firm in the clinical development phase, dedicated to the discovery, advancement, and market introduction of pioneering therapeutic agents utilizing clean-surfaced nanotechnology (CSN). CNM-Au8 stands as its flagship compound, currently under evaluation across a diverse range of clinical studies. This includes a pivotal Phase 2/3 study intended for regulatory submission in individuals battling amyotrophic lateral sclerosis (ALS).
Price
| Price | $3.86 |
| Market Cap | $49M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | -1.93 |
| EV / EBITDA | -3.38 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | 148.78% |
| Return on Invested Capital | -188.63% |
| Return on Assets | -144.35% |
| Gross Margin | -110.15% |
| Operating Margin | -10304.57% |
| Net Margin | -20059.90% |
Related companies: CNTB · CNTX · COYA · MGNX · ORMP · OVID · PLRX
Explore sector: Healthcare · Biotechnology
More sections of CLNN: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks